HLA-DRB1 and disease outcome in multiple sclerosis
| Autor: | L. Pepper, W. E. R. Ollier, M. B. Davies, Mike Boggild, Jane Worthington, Anthony A. Fryer, Carolyn A Young, C. L. A. Mann, Rachelle Donn, Richard C. Strange, Clive Hawkins, Wendy Thomson, S. J. M. Weatherby, Peter W. Jones |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Multiple Sclerosis Neurology Human leukocyte antigen Disease Severity of Illness Index Central nervous system disease immune system diseases Internal medicine medicine Humans Genetic Predisposition to Disease Age of Onset Allele HLA-DRB1 Neuroradiology business.industry Multiple sclerosis HLA-DR Antigens Middle Aged Prognosis medicine.disease Case-Control Studies Chronic Disease Immunology Disease Progression Female Neurology (clinical) business HLA-DRB1 Chains |
| Zdroj: | Journal of Neurology. 248:304-310 |
| ISSN: | 1432-1459 0340-5354 |
| Popis: | The association between susceptibility to multiple sclerosis (MS) and the class II MHC allele HLA-DRB1*15 is well established although a possible relationship between this allele and outcome in MS is less clear. HLA-DRB1 typing was performed on 375 unrelated white patients with clinically definite MS and on 367 healthy controls. Putative associations of the gene with outcome were examined by dividing patients into two groups: those with an EDSS of 0–5.5 (mild/moderate disease) and those with an EDSS of 6–10 (severe disease). In order to minimise the effects of disease variability patients with a disease duration of at least 10 years or 15 years were examined. As subsidiary HLA-DRB1*03 and HLA-DRB1*04 associations have been previously reported, the effect of these alleles was also examined. As expected, HLA-DRB1*15 was found more frequently in patients than in controls (P < 0.000001). HLA-DRB1*15 positive patients had a significantly earlier age at onset than HLA-DRB1*15 negative patients. No significant associations were noted between HLA-DRB1*15 and outcome in the total patient group or in patients with a disease duration of 10 years or longer. In patients with a disease duration of at least 15 years HLA-DRB1*15 negative status was associated with a worse prognosis, although this did not remain significant after correction for multiple testing. It is thus likely that the contribution of HLA in MS is primarily towards onset and initial triggering mechanisms rather than influencing disease progression, chronicity and severity |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink